Primer: Arcus Biosciences Inc (RCUS US) - Aug 2026
Arcus is a clinical-stage biopharmaceutical company with a deep pipeline focused on high-potential immuno-oncology targets, including TIGIT, the...
88 Views
Biopharma Week in Review - Jul 8, 2024
The cost of Kisunla is $32K/year, which is at a premium to Leqembi (Biogen, Inc. [BIIB]/Eisai Co., Ltd. [ESAIY]) at $26.5K/year, but total cost per...
386 Views
Gilead to Acquire a Stake in Arcus Biosciences; Offer May Come at a Large Premium
On 16th April 2020, Bloomberg reported that Gilead Sciences is considering acquiring a significant stake in Arcus Biosciences, a cancer...
531 Views
No more insights